Tags

Type your tag names separated by a space and hit enter

New antiepileptic drug therapies.
Neurol Clin. 2002 Nov; 20(4):1163-82.NC

Abstract

The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life. Unfortunately, many patients continue to experience refractory epilepsy despite the use of these new agents, and dose-related adverse effects and idiosyncratic reactions continue to be problematic. A recent report describes six new compounds in preclinical development, and five in clinical trials [131]. As the number of available, effective, but imperfect antiepileptic drugs increases, many challenges remain. These include: choosing the drug appropriate for the epileptic syndrome, assessing accurately the range of a drug's adverse effects in an individual patient, and considering carefully the drug's interactions in combination drug therapy. In considering drug combinations, differing mechanisms of drug action and favorable pharmacodynamic interactions (an area requiring additional studies) are of importance. Clinicians caring for children who have epilepsy anticipate further advances in the pharmacogenetics and molecular pathophysiology of epilepsy, leading to individually tailored, effective, and safe therapy.

Authors+Show Affiliations

Division of Epilepsy and Clinical Neurophysiology, Children's Hospital, 300 Longwood Avenue, HU2, Boston, MA 02115, USA. ann.bergin@tch.harvard.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12616686

Citation

Bergin, Ann M., and Mary Connolly. "New Antiepileptic Drug Therapies." Neurologic Clinics, vol. 20, no. 4, 2002, pp. 1163-82.
Bergin AM, Connolly M. New antiepileptic drug therapies. Neurol Clin. 2002;20(4):1163-82.
Bergin, A. M., & Connolly, M. (2002). New antiepileptic drug therapies. Neurologic Clinics, 20(4), 1163-82.
Bergin AM, Connolly M. New Antiepileptic Drug Therapies. Neurol Clin. 2002;20(4):1163-82. PubMed PMID: 12616686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New antiepileptic drug therapies. AU - Bergin,Ann M, AU - Connolly,Mary, PY - 2003/3/6/pubmed PY - 2003/4/4/medline PY - 2003/3/6/entrez SP - 1163 EP - 82 JF - Neurologic clinics JO - Neurol Clin VL - 20 IS - 4 N2 - The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life. Unfortunately, many patients continue to experience refractory epilepsy despite the use of these new agents, and dose-related adverse effects and idiosyncratic reactions continue to be problematic. A recent report describes six new compounds in preclinical development, and five in clinical trials [131]. As the number of available, effective, but imperfect antiepileptic drugs increases, many challenges remain. These include: choosing the drug appropriate for the epileptic syndrome, assessing accurately the range of a drug's adverse effects in an individual patient, and considering carefully the drug's interactions in combination drug therapy. In considering drug combinations, differing mechanisms of drug action and favorable pharmacodynamic interactions (an area requiring additional studies) are of importance. Clinicians caring for children who have epilepsy anticipate further advances in the pharmacogenetics and molecular pathophysiology of epilepsy, leading to individually tailored, effective, and safe therapy. SN - 0733-8619 UR - https://www.unboundmedicine.com/medline/citation/12616686/New_antiepileptic_drug_therapies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0733-8619(02)00017-8 DB - PRIME DP - Unbound Medicine ER -